Anúncio
Anúncio

NMRA

NMRA logo

Neumora Therapeutics, Inc. Common Stock

1.82
USD
Patrocinado
+0.18
+11.25%
06 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

1.96

+0.15
+7.97%

Relatórios de Lucros NMRA

Rácio de surpresa positiva

NMRA separação 5 de 9 últimas estimativas.

56%

Próximo Relatório

Data do Próximo Relatório
27 de abr. de 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.33
Mudanças implicadas de Q3 25 (Revenue/ EPS)
--
/
+3.13%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
--
/
-10.81%

Neumora Therapeutics, Inc. Common Stock earnings per share and revenue

On 06 de nov. de 2025, NMRA reported earnings of -0.32 USD per share (EPS) for Q3 25, beating the estimate of -0.34 USD, resulting in a 5.99% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.53% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analistas forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an aumentar of 3.13% EPS, and aumentar of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Citius Oncology, Inc. Common Stock
Report Date
23 de dez. de 2025 Para Q4 25
Estimativa
-$0.12
Real
-$0.06
Surpresa
+50.98%
FAQ
For Q3 2025, Neumora Therapeutics, Inc. Common Stock reported EPS of -$0.32, beating estimates by 5.99%, and revenue of $0.00, 0% as expectations.
The stock price moved down -1.53%, changed from $2.62 before the earnings release to $2.58 the day after.
The next earning report is scheduled for 27 de abr. de 2026.
Based on 10 analistas, Neumora Therapeutics, Inc. Common Stock is expected to report EPS of -$0.33 and revenue of -- for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio